Recombinant zoster vaccine should go on NIP, says PBAC
The recombinant zoster vaccine Shingrix has received PBAC approval for patients aged 70 and for immunocompromised adults at high risk of zoster infection. Aboriginal and…
The recombinant zoster vaccine Shingrix has received PBAC approval for patients aged 70 and for immunocompromised adults at high risk of zoster infection. Aboriginal and…
Elderly patients should be treated with as low a dose as possible, researchers say.
The patient suffered a bullous drug eruption after her second dose of Shingrix, US doctors report.
It may be another couple of years before it is subsidised for the elderly.
But there'll be a wait before it's even considered for subsidy under the NIP.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.